SHERIDAN, WYOMING – May 19, 2025 – Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, has announced the successful completion of a $250 million strategic investment from global investment powerhouse KKR. The transaction marks a pivotal growth move, with KKR acquiring approximately 12% of Henry Schein’s common shares and strengthening its governance role with the appointment of two prominent executives to the company’s Board of Directors.
Strategic Growth Backed by Capital and Expertise
This investment by KKR represents a significant endorsement of Henry Schein’s strategic direction and operational performance. With a growing global footprint and more than $12.7 billion in 2024 sales, Henry Schein continues to evolve its service offerings to meet the complex needs of modern health care providers. The infusion of capital is expected to support the company’s BOLD+1 strategy, which is focused on enhancing long-term stakeholder value through innovation, operational excellence, and strategic partnerships.
William K. “Dan” Daniel, a seasoned executive with over three decades of experience in the industrial and health care sectors, has joined the Henry Schein Board of Directors as an independent director. Daniel’s deep operational background, particularly his 14-year tenure as Executive Vice President at Danaher Corporation, brings critical insight to the company’s leadership team.
He is joined on the board by Max Lin, Partner at KKR and head of the firm’s Health Care industry team in the Americas. Lin was appointed earlier this month and brings substantial expertise in investments across dental services, medical equipment, and health care IT.
Enhanced Board Leadership for Strategic Governance
With these appointments, Henry Schein strengthens its governance structure by integrating operational and investment acumen from two highly experienced leaders. Their appointments to key board committees reflect a deliberate strategy to align capital investment with actionable oversight.
- Dan Daniel has been appointed to the Compensation Committee.
- Max Lin has been appointed Vice Chair of the Nominating and Governance Committee.
- Both Daniel and Lin will serve on the Strategic Advisory Committee.
“We are pleased to welcome Max and Dan to the Board as we embark on this exciting next chapter for Henry Schein,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Their deep experience in health care, operations, and strategic growth will be invaluable as we continue executing on our BOLD+1 strategy and creating long-term value for our stakeholders.”
Aligning with Industry Dynamics and Health Care Evolution
The health care industry is undergoing rapid transformation, driven by digital innovation, supply chain complexity, and a shift toward integrated care delivery. Henry Schein’s portfolio of more than 300 solutions supports more than 1 million customers globally, including dental practices, medical offices, laboratories, and institutional clinics.
This strategic partnership with KKR positions Henry Schein to:
- Accelerate innovation in health care services and technology.
- Expand global reach and operational scalability.
- Strengthen its position in the dental and medical practitioner markets.
KKR’s collaborative investment approach and track record in health care make it a natural partner for Henry Schein’s ambitious growth roadmap.
A Future-Focused Collaboration with High-Value Outcomes
By leveraging KKR’s capital and network alongside board-level leadership from proven industry veterans, Henry Schein is reinforcing its commitment to scalable innovation, global market expansion, and operational excellence.
As both companies look ahead, the partnership underscores a shared vision to deliver sustainable value and strategic differentiation in the evolving B2B health care ecosystem.
Learn more at www.henryschein.com.